Form 4: Champions Oncology Director Acquires Stock Options

Scott R. Tobin, a director at Champions Oncology, Inc., has acquired 34,550 stock options.

Summary

• Scott R. Tobin, a director at Champions Oncology, Inc., acquired 34,550 stock options on November 12, 2024.
• The options have an exercise price of $4.64 per share.
• The options vest over a twelve-month period, with vesting dates on November 12, 2024, February 12, 2025, May 12, 2025, and August 12, 2025.
• The options expire on November 12, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it aligns director interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options by a director may indicate confidence in the company's future performance.

Industry Context

This is a standard transaction for a director of a public company, often used as part of compensation packages to align the interests of management with shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
• The vesting schedule of 12 months is fairly standard, often with quarterly or annual vesting periods.
• The exercise price is typically set at or near the market price of the stock at the time of the grant.

Stakeholder Impact

• The stock option grant could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, Champions Oncology, director, equity, CSBR, Scott R. Tobin